Should Exact Sciences Stock Stay in Your Portfolio Right Now?

Exact Sciences Corporation (EXAS) is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is encouraging. Additionally, the company is advancing digital infrastructure and diagnostics to deliver comprehensive insights at every stage of cancer care. Meanwhile, mounting costs from macroeconomic pressures and overreliance on the Cologuard test raise concerns.In the past year, this Zacks Rank #3 (Hold) stock ...